mTOR Signaling Confers Resistance to Targeted Cancer Drugs

Guri, Yakir and Hall, Michael N.. (2016) mTOR Signaling Confers Resistance to Targeted Cancer Drugs. Trends in Cancer, 2 (11). pp. 688-697.

[img] PDF - Published Version
Restricted to Repository staff only


Official URL: http://edoc.unibas.ch/51836/

Downloads: Statistics Overview


Cancer is a complex disease and a leading cause of death worldwide. Extensive research over decades has led to the development of therapies that target cancer-specific signaling pathways. However, the clinical benefits of such drugs are at best transient due to tumors displaying intrinsic or adaptive resis- tance. The underlying compensatory pathways that allow cancer cells to cir-cumvent a drug blockade are poorly understood. We review here recent studies suggesting that mammalian TOR (mTOR) signaling is a major compensatory pathway conferring resistance to many cancer drugs. mTOR-mediated resis-tance can be cell-autonomous or non-cell-autonomous. These findings suggest that mTOR signaling should be monitored routinely in tumors and that an mTOR inhibitor should be considered as a co-therapy.
Faculties and Departments:05 Faculty of Science > Departement Biozentrum > Growth & Development > Biochemistry (Hall)
UniBasel Contributors:Hall, Michael N.
Item Type:Article, refereed
Article Subtype:Research Article
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
edoc DOI:
Last Modified:05 Jun 2019 08:19
Deposited On:13 Jul 2017 09:40

Repository Staff Only: item control page